Comparison of the grade of concordance in terms of K-ras status between primaries and related liver metastases in colorectal cancer

Chinese Journal of Cancer Prevention and Treatment

Volumn 17, Issue 12, 2010, Pages 926-929

  Xian, Hai Bing ^a   Yu, Hong Bo ^b   Zhang, Ji Ren ^a  

^a SOUTHERN MEDICAL UNIVERSITY   (China)

^b SHANDONG CANCER HOSPITAL AND INSTITUTE   (China)

Author keywords

Colorectal neoplasms; Gene, K ras; Liver neoplasms secondary; Mutation

Indexed keywords

DNA; FORMALDEHYDE;

ARTICLE; CANCER GRADING; COLORECTAL CANCER; DNA DETERMINATION; DNA EXTRACTION; GENE AMPLIFICATION; GENE MUTATION; GENE SEQUENCE; HUMAN; LIVER METASTASIS; MAJOR CLINICAL STUDY; ONCOGENE K RAS; POLYMERASE CHAIN REACTION; PRIMARY TUMOR; QUALITY CONTROL; TREATMENT RESPONSE;

EID: 77957903577     PISSN: 16735269     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. Parkin D M, Bray F, Ferlay J, et al. Global cancer statistics, 2002. [J] CA Cancer J Clin, 2005,55(2):74-108.
2. Kemeny N. Management of liver metastases from colorectal cancer[J]. Oncology, 2006,20(10):1161-1176.
3. Rusthoven K E, Kavanagh B D, Cardenes H, et al. Multi-institutional phase I/II trial of stereotactic body radiation therapy for liver metastases.[J] J Clin Oncol, 2009,27(10):1572-1578.
4. Cunningham D, Humblet Y, Siena S, et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer[J]. N Engl J Med, 2004,351(4):337-345.
5. Lievre A, Bachet J B, Le Corre D, et al. KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer[J]. Cancer Res, 2006,66(8):3992-3995.
6. Benvenuti S, Sartore-Bianchi A, Di Nicolantonio F, et al. Oncogenic activation of the RAS/RAF signaling pathway impairs the response of metastatic colorectal cancers to anti-epidermal growth factor receptor antibody therapies[J]. Cancer Res, 2007,67(6):2643-2648.
7. Di Fiore F, Blanchard F, Charbonnier F, et al. Clinical relevance of KRAS mutation detection in metastatic colorectal cancer treated by cetuximab plus chemotherapy[J]. Br J Cancer, 2007,96(8):1166-1169.
8. Khambata-Ford S, Garrett C R, Meropol NJ, et al. Expression of epiregulin and amphiregulin and K-ras mutation status predict disease control in metastatic colorectal cancer patients treated with cetuximab[J]. J Clin Oncol, 2007,25(22):3230-3237.
9. Lievre A, Bachet J B, Boige V, et al. KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab[J]. J Clin Oncol, 2008,26(3):374-379.
10. Amado RG, Wolf M, Peeters M, et al. Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer[J]. J Clin Oncol, 2008,26(10):1626-1634.
11. Doolittle B R, Emannel J, Tuttle C, et al. Detection of the mutated K-ras biomarker in colorectal carcinoma[J]. Exp Mol Pathol, 2001,70(3):289-301.
12. Bos J L. Ras oncogenes in human cancer. A review[J]. Cancer Res, 1989,49(17):4682-4689.
13. Halatsch M E, Hirsch K I, Weinel R J, et al. Differential activation of the c-K-ras-2 proto-oncogene in human colorectal carcinoma[J]. Anti-cancer Res, 1998,18(4A):2323-2325.
14. Doolittle B R, Emannel J, Tuttle C, et al. Detection of the mutated K-ras biomarker in colorectal carcinoma[J]. Exp Mol Pathol, 2001,70(3):289-301.
15. Wu C M, Tang R, Wang J Y, et al. Frequency and spectrum of K-ras codons 12 and 13 mutations in colorectal adenocarcinomas from Taiwan[J]. Cancer Genet Cytogenet, 2005,158(1):55-60.
16. Kinoshita H, Yanagisawa A, Watanabe T, et al. Increase in the frequency of K-ras codon 12 point mutation in colorectal carcinoma in elderly males in Japan: the 1990s compared with the 1960s[J]. Cancer Sci, 2005,96(4):218-220.
17. Oliveira C, Velho S, Moutinho C, et al. KRAS and BRAF oncogenic mutations in MSS colorectal carcinoma progression[J]. Oncogene, 2007,26(1):158-163.
18. Molinari F, Martin V, Bordoni A, et al. Analysis of epidermal growth factor receptor(EGFR) gene status and protein expression, and K-ras gene mutation in metastatic colorectal cancer patients: Comparison between primary tumor and related metastatic sites[J]. Ann Oncol, 2008,19(Suppl 1):i10-i25.
19. Daniele S, Fotios L, Bruno V, et al. High concordance of KRAS status between primary colorectal tumors and related metastatic sites: implication for clinical practice[J]. The Oncologist, 2008,13(10):1270-1275.
20. Fotios L, Luca P, Irene S, et al. PTEN Expression and KRAS Mutations on Primary Tumors and Metastases in the Prediction of Benefit From Cetuximab Plus Irinotecan for Patients With Metastatic Colorectal Cancer[J]. J Clin Oncol, 2009,27(16):2622-2639.